Gigi N C Chiu

List of Publications by Year
in descending order

53 papers	6,992 citations	201674 27 h-index	189892 50 g-index
54 all docs	54 docs citations	54 times ranked	17026 citing authors

#	Article	IF	Citations
1	Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem and Progenitor Cells from Non-Enriched Umbilical Cord Blood with Azole Compounds. Stem Cells Translational Medicine, 2018, 7, 376-393.	3.3	23
2	Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. Advanced Materials, 2018, 30, e1802368.	21.0	149
3	Application of Static Modeling ÂÂin the Prediction of In Vivo Drugâ€“Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies. Drug Metabolism and Disposition, 2017, 45, 260-268.	3.3	31
4	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
5	Small Molecule Based Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem & Progenitor Cells from Non-Enriched Umbilical Cord Blood Mononucleated Cells. Blood, 2016, 128, 2321-2321.	1.4	1
6	Dual-functionalized poly(amidoamine) dendrimers with poly(ethylene glycol) conjugation and thiolation improved blood compatibility. Journal of Pharmacy and Pharmacology, 2015, 67, 1492-1502.	2.4	15
7	Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. Journal of Controlled Release, 2015, 220, 438-446.	9.9	48
8	Mitochondrial superoxide reduction and cytokine secretion skewing by carbon nanotube scaffolds enhance ex vivo expansion of human cord blood hematopoietic progenitors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1643-1656.	3.3	9
9	Synthesis and biological activity of fluorinated 7-benzylamino-2-phenyl-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-amines. Journal of Fluorine Chemistry, 2015, 175, 68-72.	1.7	12
10	Dendrimers in Oral Drug Delivery Application: Current Explorations, Toxicity Issues and Strategies for Improvement. Current Pharmaceutical Design, 2015, 21, 2629-2642.	1.9	38
11	Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia. Nanomedicine, 2014, 9, 1665-1679.	3.3	14
12	Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II. European Journal of Medicinal Chemistry, 2014, 78, 294-303.	5.5	28
13	Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. Journal of Controlled Release, 2013, 172, 852-861.	9.9	59
14	Fragment-based approach to the design of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines as thymidine phosphorylase inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 400-410.	5.5	34
15	Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian Journal of Pharmaceutical Sciences, 2013, 8, 88-95.	9.1	113
16	Protective role of functionalized single walled carbon nanotubes enhance ex vivo expansion of hematopoietic stem and progenitor cells in human umbilical cord blood. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1304-1316.	3.3	22
17	Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolide-induced apoptosis. International Journal of Oncology, 2013, 42, 1605-1612.	3.3	59
18	SIMULTANEOUS DETERMINATION OF DOXORUBICIN AND IRINOTECAN IN CONJUNCTION WITH THEIR MAJOR METABOLITES BY ULTRA HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Journal of Liquid Chromatography and Related Technologies, 2013, 36, 914-925.	1.0	7

#	Article	IF	Citations
19	Expansion Culture Of Hematopoietic Stem & Progenitor Cells From Frozen-Thawed, Non-Enriched Human Umbilical Cord Blood In Animal Componentâ€“ & Serumâ€“Free Medium Enhances Engraftment & Reduces Graft-Versus-Host-Disease. Blood, 2013, 122, 4460-4460.	1.4	0
20	Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. Journal of Controlled Release, 2013, 172, 852-61.	9.9	18
21	Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. International Journal of Nanomedicine, 2012, 7, 651.	6.7	53
22	Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. International Journal of Nanomedicine, 2012, 7, 739.	6.7	30
23	Intercellular cytosolic transfer correlates with mesenchymal stromal cell rescue of umbilical cord blood cell viability during ex vivo expansion. Cytotherapy, 2012, 14, 1064-1079.	0.7	14
24	Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration. International Journal of Pharmaceutics, 2012, 430, 167-175.	5.2	43
25	In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. Journal of Controlled Release, 2012, 160, 290-298.	9.9	21
26	The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death and Disease, 2011, 2, e129-e129.	6.3	124
27	Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action andin vivoactivity. Nanomedicine, 2011, 6, 1575-1591.	3.3	18
28	Functionalized carbon nanomaterials: exploring the interactions with Caco-2 cells for potential oral drug delivery. International Journal of Nanomedicine, 2011, 6, 2253.	6.7	33
29	Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncology Reports, 2011, 26, 1315-21.	2.6	19
30	Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin. International Journal of Oncology, 2011, 40, 703-10.	3.3	3
31	Role of reactive oxygen species in the synergistic cytotoxicity of safingol-based combination regimens with conventional chemotherapeutics. Oncology Letters, 2011, 2, 905-910.	1.8	7
32	Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 834-840.	3.3	116
33	Functionalized Carbon Nanotubes Increase the Viability of Post-Thaw Cord Blood Cells and Enhance the Overall Hematopoietic Progenitor Cell Expansion in Ex Vivo Culture. Blood, 2011, 118, 1327-1327.	1.4	0
34	Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anti-Cancer Drugs, 2010, 21, 401-410.	1.4	64
35	The functional roles of poly(ethylene glycol)â€lipid and lysolipid in the drug retention and release from lysolipidâ€containing thermosensitive liposomes in vitro and in vivo. Journal of Pharmaceutical Sciences, 2010, 99, 2295-2308.	3.3	98
36	In Vitro Efficacy of a Novel Liposomal Formulation of a Protein Kinase C Inhibitor In the Treatment of Acute Myeloid Leukemia. Blood, 2010, 116, 3282-3282.	1.4	0

#	Article	IF	Citations
37	DEVELOPMENT AND CHARACTERIZATION OF A NANOCARRIER FOR QUERCETIN. International Journal of Nanoscience, 2009, 08, 175-179.	0.7	2
38	Synthesis and Heterocyclizations of 3,4-Dihydroquinazolin-2-yl Guanidine in the Search of New Anticancer Agents. Heterocycles, 2009, 78, 1761.	0.7	18
39	The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. International Journal of Oncology, 2009, 35, 1463-71.	3.3	12
40	Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities. Current Drug Metabolism, 2009, 10, 861-874.	1.2	49
41	Synthesis and biological activity of fluorinated 7-aryl-2-pyridyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines. Journal of Fluorine Chemistry, 2008, 129, 429-434.	1.7	31
42	Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. International Journal of Pharmaceutics, 2008, 349, 38-46.	5.2	58
43	Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). Molecular Cancer Therapeutics, 2008, 7, 59-70.	4.1	62
44	A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity. Letters in Drug Design and Discovery, 2007, 4, 426-433.	0.7	5
45	Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics, 2007, 6, 844-855.	4.1	54
46	Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations. Letters in Drug Design and Discovery, 2006, 3, 704-713.	0.7	1
47	Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. Journal of Controlled Release, 2005, 104, 271-288.	9.9	108
48	Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1611, 63-69.	2.6	7
49	Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1613, 115-121.	2.6	32
50	Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1560, 37-50.	2.6	27
51	Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. Journal of Controlled Release, 2002, 84, 161-170.	9.9	83
52	Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol). Bioscience Reports, 2002, 22, 225-250.	2.4	367
53	Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochimica Et Biophysica Acta - Biomembranes, 2001, 1510, 56-69.	2.6	52